RecruitingNCT06015776

Purinergic Signaling and the Postmenopausal Heart

PGC-1, Purines and the Postmenopausal Heart


Sponsor

Beth Israel Deaconess Medical Center

Enrollment

100 participants

Start Date

Jul 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.


Eligibility

Min Age: 30 YearsMax Age: 88 Years

Inclusion Criteria1

  • Patients undergoing cardiac surgery under cardiopulmonary bypass.

Exclusion Criteria8

  • Refusal to participate
  • Emergency surgery
  • Pre-existing heart block
  • Preexisting atrial fibrillation
  • Redo surgery
  • Estrogen or hormone replacement therapy
  • History of chronic heart failure
  • History of major kidney disease

Interventions

OTHERGender

Differences between men and women will be observed


Locations(1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06015776


Related Trials